Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of dose-escalated radiation therapy to usual care in patients with locally advanced unresectable pancreatic ductal adenocarcinoma who have received an initial 4-6 months of chemotherapy. Usual care …
Sponsor: NRG Oncology
NCT ID: NCT06958328
Sites in Wisconsin: - Langlade Hospital and Cancer Center — Antigo, Wisconsin
- Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
- Aurora Cancer Care-Grafton — Grafton, Wisconsin
Phase 3 Recruiting Network
This phase III trial compares the effect of adding panitumumab to standard chemotherapy (with nanoliposomal Irinotecan, leucovorin, and 5-fluorouracil \[5-FU\] or irinotecan, leucovorin, and 5-FU or nab-paclitaxel and gemcitabine) versus s…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06998940
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Essentia Health-Hayward Clinic — Hayward, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard chemotherapy with or without INCB161734 in participants with metastatic pancreatic ductal adenocarcinoma (PDAC).
Sponsor: Incyte Corporation
NCT ID: NCT07522073
Sites in Wisconsin: - Investigative Site US044 — Madison, Wisconsin
Phase 3 Recruiting Industry
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting o…
Sponsor: Pierre Fabre Medicament
NCT ID: NCT03394365
Sites in Wisconsin: - Froedtert and Medical College of Wisconsin - Clinical Cancer Center (Adults only) — Milwaukee, Wisconsin
Phase 2, Phase 3 Recruiting Industry
The primary purpose of this study is to assess the effectiveness of zanzalintinib compared to everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors.
Sponsor: Exelixis
NCT ID: NCT06943755
Sites in Wisconsin: - Exelixis Clinical Site #31 — Milwaukee, Wisconsin
Phase 2 Recruiting NIH
This phase II trial investigates how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04858334
Sites in Wisconsin: - ThedaCare Regional Cancer Center — Appleton, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Saint Vincent Hospital Cancer Center Green Bay — Green Bay, Wisconsin
- Saint Vincent Hospital Cancer Center at Saint Mary's — Green Bay, Wisconsin
- Mercyhealth Hospital and Cancer Center - Janesville — Janesville, Wisconsin
Phase 2 Recruiting Network
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05040360
Sites in Wisconsin: - Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Essentia Health-Hayward Clinic — Hayward, Wisconsin
- Tamarack Health Hayward Medical Center — Hayward, Wisconsin
Phase 2 Recruiting Academic/Other
This phase II study evaluates how well pemigatinib works for the treatment of adult patients with pancreatic cancer that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has s…
Sponsor: Sameek Roychowdhury
NCT ID: NCT06906562
Sites in Wisconsin: - Ohio State University Telemedicine — Chippewa Falls, Wisconsin
- Ohio State University Telemedicine — Green Bay, Wisconsin
- Ohio State University Telemedicine — Madison, Wisconsin
- Ohio State University-Telemedicine — Milwaukee, Wisconsin
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial studies the safety, side effects and best dose of M3814 and to see how well it works when given together with radiation therapy in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nod…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04172532
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - Eastpark Medical Center — Madison, Wisconsin
- University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the bo…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06428409
Sites in Wisconsin: - University Hospital and UW Health Clinics-Carbone Cancer Center ( Site 0293) — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation and dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Spevatamig (PT886). Pa…
Sponsor: Phanes Therapeutics
NCT ID: NCT05482893
Sites in Wisconsin: - University of Wisconsin Carbone Cancer Center - University Hospital — Madison, Wisconsin
Phase 1, Phase 2 Recruiting Industry
Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.
Sponsor: Perspective Therapeutics
NCT ID: NCT06710756
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Industry
To assess: * efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CN…
Sponsor: Apollomics Inc.
NCT ID: NCT03175224
Sites in Wisconsin: - University of Wisconsin — Madison, Wisconsin
Phase 2 Recruiting Academic/Other
The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. …
Sponsor: Gulam Manji
NCT ID: NCT04543071
Sites in Wisconsin: - Medical College of Wisconsin, Wisconsin Diagnostic Labratories — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This is an open-label, phase II study in patients with resectable and borderline resectable pancreatic cancer.
Sponsor: Medical College of Wisconsin
NCT ID: NCT04683315
Sites in Wisconsin: - Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.
Sponsor: Medical College of Wisconsin
NCT ID: NCT03322995
Sites in Wisconsin: - Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT05245500
Sites in Wisconsin: - Local Institution - 108 — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Wisconsin: - University of Wisconsin - Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyltransferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
Sponsor: Kura Oncology, Inc.
NCT ID: NCT06026410
Sites in Wisconsin: - University of Wisconsin (Carbone Cancer Center) — Madison, Wisconsin
Phase 1 Recruiting Industry
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
Sponsor: AstraZeneca
NCT ID: NCT06218914
Sites in Wisconsin: - Research Site — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Researchers are looking at ways to attack CLDN18.2 to help control tumors. ASP2138 is thought to bind to CLDN18.2 and a…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT05365581
Sites in Wisconsin: - Froedtert Hospital and the Medical College of Wisconsin — Milwaukee, Wisconsin
Phase 1 Recruiting Industry
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Sponsor: I-Mab Biopharma US Limited
NCT ID: NCT04900818
Sites in Wisconsin: - UW Carbone Cancer Center — Madison, Wisconsin
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Wisconsin: - Froedtert Hospital & the Medical College of Wisconsin — Milwaukee, Wisconsin
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Wisconsin: - Aspirus Cancer Care-Antigo-Volm Cancer Center — Antigo, Wisconsin
- ThedaCare Regional Cancer Center — Appleton, Wisconsin
- ThedaCare Regional Medical Center - Appleton — Appleton, Wisconsin
- Duluth Clinic Ashland — Ashland, Wisconsin
- Northwest Wisconsin Cancer Center — Ashland, Wisconsin
Recruiting Network
The purpose of this study is to compare two approaches for monitoring pancreatic cysts as well as to identify associated biomarkers. The study doctors want to compare more frequent monitoring versus less frequent monitoring as well as iden…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT04239573
Sites in Wisconsin: - Aurora Cancer Care-Southern Lakes VLCC — Burlington, Wisconsin
- Aurora Saint Luke's South Shore — Cudahy, Wisconsin
- Marshfield Medical Center-EC Cancer Center — Eau Claire, Wisconsin
- Aurora Health Care Germantown Health Center — Germantown, Wisconsin
- Aurora Cancer Care-Grafton — Grafton, Wisconsin